Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00450281 · ClinicalTrials.gov registry record

S0424 - Carcinogens in Lung Tissue From Smokers (Closed to Entry as of 7/15/07) and Non-Smokers With Newly Diagnosed Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer

A clinical trial of Lung Cancer, sponsored by SWOG Cancer Research Network.

Completed
Registry status
981
Enrollment target
20
Study locations

NCT00450281: Completed study of Lung Cancer, sponsored by SWOG Cancer Research Network.

NCT00450281 is a study of Lung Cancer that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 981 participants, roughly in line with the 933-participant average among 409 other Lung Cancer trials with a reported enrollment target. The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00450281, a study of Lung Cancer, has completed, sponsored by SWOG Cancer Research Network.

COMPLETED
Registry status
981 participants
Enrollment target
20
Study locations

Study Summary

RATIONALE: Studying samples of blood and tissue from smokers (closed to entry as of 7/15/07) and non-smokers with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors learn more about risk factors for lung cancer and may help the study of cancer in the future. PURPOSE: This clinical trial is studying carcinogens in lung tissue from smokers (closed to entry as of 7/15/07) and non-smokers with newly diagnosed stage I, stage II, or stage III non-small cell lung cancer.

Conditions Studied

Lung Cancer

Interventions

  • GENETIC gene expression analysis
  • GENETIC mutation analysis
  • GENETIC polymerase chain reaction
  • GENETIC polymorphism analysis
  • GENETIC chromogenic in situ hybridization

Study Locations (20)

California

  • Kaiser Permanente - Deer Valley - Antioch
  • Roy and Patricia Disney Family Cancer Center at Providence Saint Joseph Medical Center - Burbank
  • Cancer Care Center at John Muir Health - Concord Campus - Concord
  • North Bay Cancer Center - Fairfield
  • Kaiser Permanente - Fremont - Fremont
  • Glendale Memorial Hospital Comprehensive Cancer Center - Glendale
  • Kaiser Permanente Medical Center - Hayward - Hayward
  • Tibotec Therapeutics - Division of Ortho Biotech Products, LP - Marysville
  • Kaiser Permanente Medical Center - Oakland - Oakland
  • Chao Family Comprehensive Cancer Center at University of California Irvine Medical Center - Orange
  • Valley Care Medical Center - Pleasanton
  • Robert and Beverly Lewis Family Cancer Care Center at Pomona Valley Hospital Medical Center - Pomona
  • Kaiser Permanente Medical Center - Redwood City - Redwood City
  • Kaiser Permanente Medical Center - Richmond - Richmond
  • Kaiser Permanente Medical Center - Roseville - Roseville
  • University of California Davis Cancer Center - Sacramento
  • Mercy General Hospital - Sacramento

Alaska

  • Providence Cancer Center - Anchorage

Arizona

  • Arizona Cancer Center at University of Arizona Health Sciences Center - Tucson

Arkansas

  • Hembree Mercy Cancer Center at St. Edward Mercy Medical Center - Fort Smith

Trial Details

FieldValue
Enrollment Target 981 participants
Start Date 2005-10
Est. Completion 2012-07
SWOG Cancer Research Network

270 total trials

What the finished NCT00450281 record still lists

NCT00450281 is an observational study that tracks outcomes without assigning an intervention. The registered 981 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 933-participant average among 409 other Lung Cancer trials with a reported enrollment target.

The record links to 1 condition, with Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which gene expression analysis is the first listed.

NCT00450281 names 20 study sites across 4 states, led by California, Alaska, Arizona.

Frequently Asked Questions

What is clinical trial NCT00450281 about?

NCT00450281 is a clinical study titled "S0424 - Carcinogens in Lung Tissue From Smokers (Closed to Entry as of 7/15/07) and Non-Smokers With Newly Diagnosed Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer". RATIONALE: Studying samples of blood and tissue from smokers (closed to entry as of 7/15/07) and non-smokers with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors learn more about risk factors for...

What is the current status of trial NCT00450281?

This trial is currently completed. The enrollment target is 981 participants. The study started on 2005-10. Estimated completion is 2012-07.

What conditions does trial NCT00450281 study?

This clinical trial studies the following conditions: Lung Cancer.

What interventions are being tested in trial NCT00450281?

The interventions under investigation include: gene expression analysis (GENETIC), mutation analysis (GENETIC), polymerase chain reaction (GENETIC), polymorphism analysis (GENETIC), chromogenic in situ hybridization (GENETIC).

Who is sponsoring clinical trial NCT00450281?

This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00450281 being conducted?

This trial has 20 study locations across Alaska, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00450281's enrollment target sits among peer trials

981 51st of 409 higher than 359 of 409 other Lung Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06959095 · 981 participants · Phase 3

    Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1)

  • NCT06989437 · 982 participants · Phase 2

    A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

  • NCT06337097 · 980 participants · NA

    STRICT - Surveillance With TRoponin During Immune Checkpoint Therapy

  • NCT07070232 · 980 participants · Phase 1

    A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00450281, the US trial registry maintained by the National Library of Medicine. NCT00450281 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.